Elusys receives notice of allowance on anti-anthrax antibody patent
The patent covers methods of preventing or treating anthrax with ETI-204 along with antibiotics. The patent also includes claims on intramuscular injection as a route of administration for ETI-204. Anthrax antitoxins currently stockpiled by the U.S. are administered solely through intravenous infusion.
The notice of allowance recognizes methods of preventing inhalation anthrax with ETI-204 before or after exposure to Bacillus anthracis, combined with antibiotics typically used to treat inhaled anthrax. Elusys said ETA-204 is a potential candidate for future acquisition into the U.S. Strategic National Stockpile.
"The patent allowance highlights the potential dosing flexibility of ETI-204, administered via intramuscular injection, for emergency use," Elizabeth Posillico, the president and CEO of Elusys, said. "This notice of allowance follows the recent milestone achieved when we completed enrollment of three Phase III safety studies of ETI-204 for intravenous infusion in adult volunteers, as well as a pharmacokinetics and tolerability study of ETI-204 for IM injection."
Elusys said ETI-204 is the only anthrax anti-toxin in advanced stages of development that is being investigated for both IV treatment and IM prophylaxis administration. IM injection allows for more rapid administration in prophylaxis or when IV administration is not feasible.
ET-204 works by binding to protective antigen or lethal factor, the proteins that work together to produce deadly anthrax toxins.
Elusys is focused on the development of antibody therapeutics for the treatment of infectious disease. The company has received multiple contracts and grants worth more than $200 million to support the development of ETA-204.